CNBC's David Faber reports the latest on Valeant and Pershing Square's efforts to acquire Allergan.
Discussing the fundamental concern of management for Citigroup, with Richard Bove, Rafferty Capital.
Yum Brands is reporting Q1 EPS of $0.87 ex-items on revenues of $2.72 billion, with CNBC's Sara Eisen.
Dan Nathan of Risk Reversal shorts Netflix's momentum. FM trader Guy Adami weighs in on the trade.
The "Fast Money" traders dissect Brian Kelly's trade on FireEye.
The court is worried broadcasters' challenge may hurt cloud computing, reports CNBC's Hampton Pearson with the latest details on the lawsuit.
Fast Money trader Stephanie Link shares her bullish play on McDonald's, while Stephen Weiss, takes a bearish view of the stock.
Mark Mahaney, RBC Capital Markets, breaks down Netflix's quarterly results and weighs in on the company raising rates and reporting profits in international markets.
Option traders were either lucky or knew something in advance of the Allergan news. Fast Money trader Jon Najarian, provides insight.
CNBC's Kate Kelly has the latest details on Bill Ackman and Valeant's bid for Allergan.
Mike Mayo, CLSA bank analyst, shares his thoughts on Citigroup's senior management and the outlook on the big bank.
Citigroup directors were all re-elected and KPMG was approved as auditor, reports CNBC's Kayla Tausche with the latest details from the big bank's shareholder meeting.
These companies have a lot of money and are signaling what they plan to do going forward, reports CNBC's Meg Tirrell on the mega deals in big pharma.
CNBC's Simon Hobbs reports on all the market moving events in Europe today, including consumer confidence in the euro zone and a spike in the biotech and pharma sectors.
The Fast Money traders share their final trades of the day.
The Fast Money traders take a look at today's biggest market movers.
Dennis Gartman of the Gartman Letter shares his position on equities and the best way to play a possible merger between Barrick Gold and Newmont Mining.
Michael Patcher, Wedbush Securities, discusses metrics hit by Netflix in its quarterly earnings report.
Mike Weinstein, JPMorgan senior medical technology analyst, looks at the growth acceleration story of Covidien and weighs in on Valeant's potential acquisition of Allergan.
CNBC's Meg Tirrell reports on the statement released by Valeant about its potential acquisition of Allergan.